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Statin treatmentSeveral studies have reported that statins occasionally cause impairment of liver functions characterized
by elevated serum bilirubin levels, which might be due to altered function of the multidrug resistance-
associated proteins (Mrp2/3). We aimed to study the modulation of the hepatobiliary transport of
bilirubin by four statin derivatives, atorvastatin, ﬂuvastatin, pravastatin, and rosuvastatin in sandwich-
cultured rat hepatocytes. All statins except pravastatin signiﬁcantly inhibited the uptake of bilirubin.
The biliary efﬂux of bilirubin conjugates was increased by pravastatin and rosuvastatin concentration
dependently. Rosuvastatin stimulated not only the Mrp2 mediated biliary, but the Mrp3 mediated sinu-
soidal elimination, resulting in decreased intracellular bilirubin accumulation. The signiﬁcantly induced
Mrp2/3 protein levels (ranging from 1.5 to 1.8-fold) accounted for the elevated efﬂux. Cell polarization,
the formation of biliary network was also signiﬁcantly increased by ﬂuvastatin, pravastatin and rosuvast-
atin (151%, 216% and 275% of the control, respectively). The simultaneous inhibition of the uptake and the
stimulation of the sinusoidal and canalicular elimination may explain, at least in part, the clinical obser-
vation of elevated serum bilirubin levels. In conclusion, our results suggest that in spite of the elevated
serum bilirubin levels, the altered Mrp2 and Mrp3 functions by statins is probably not associated with
hepatotoxic effects.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
inhibitors, known as statins, are one of the most broadly used cho-
lesterol lowering compounds (Hebert et al., 1997; Lewis et al., 1998;
Maron et al., 2000). Although statins have a good safety proﬁle,
orally administered statins have been reported to induce prolonged
(Bruggisser et al., 2010; Clarke and Mills, 2006; Famularo et al.,2007; Geoghegan et al., 2004; Merli et al., 2010) or even fatal chole-
stasis (Clarke andMills, 2006; Perger et al., 2003; Sreenarasimhaiah
et al., 2002) in some individuals associated with elevated serum
aminotransferase and bilirubin levels. The mechanisms by which
statins induce hepatic adverse changes are not known. Cholestasis
is referred by jaundice with a concurrent elevation in alkaline phos-
phatase, c-glutamyl transpeptidase (GGT), and conjugated bilirubin
with little or no impairment in serum transaminase values (Holt and
Ju, 2006; Mohi-ud-din and Lewis, 2004). However, any persistent
abnormality in liver transaminases levels should be treated with
caution. The elevation of serum aminotransferase in human does
not appear to correlate with hepatotoxicity (Bader, 2010) and
mild-to-moderate elevations in serum levels of liver transaminases
constitute a regular response in patients undergoing statin therapy
(Armitage, 2007; Chalasani et al., 2004; Jacobson, 2006; Parra and
Reddy, 2003; Talbert, 2006; Vuppalanchi et al., 2005). Moreover,
Bjornsson and Olsson (2005) conﬁrmed that bilirubin was the only
reliable indicator of drug induced cholestatic liver injury. It is not
possible to establish causality between statin treatment and sys-
temic bilirubin levels based on available data (Mol et al., 1988;
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mation concerning the impact of statin treatment on bilirubin hepa-
tic disposition.
In the blood circulation, bilirubin is mostly unconjugated and is
tightly bound to albumin (Brodersen, 1980; Tenhunen et al., 1968).
Bilirubin is taken up rapidly by hepatocytes partly by facilitated dif-
fusion (Iga et al., 1979; Wolkoff et al., 1979 and Zucker et al., 1999),
and partly mediated by organic anion transporter proteins (in
humans, OATP1B1 and OATP1B3; in rodents, Oatp1a4) (Briz et al.,
2006; Cui et al., 2001; Konig et al., 2000; Reichel et al., 1999; Roy
Chowdhury et al., 2001). Bilirubin is extensively metabolized to
mono- and diglucuronide conjugates by UDP-glucuronosyltransfer-
ase 1a1 (UGT1A1) (Bosma et al., 1994; Burchell, 1981; Halac and
Sicignano, 1969). Under conditions of normal liver function, biliru-
bin conjugates are eliminated across the canalicularmembrane into
bile canaliculus via multidrug resistance-associated protein 2
(human/rodent; MRP2/Mrp2) (Jedlitschky et al., 1997; Kamisako
et al., 1999; Keppler and Konig, 2000), themajor determinant of bile
salt independent bile ﬂow (Paulusma et al., 1999; Trauner et al.,
1998). When canalicular secretion is impaired, sinusoidally
expressing MRP3/Mrp3 facilitates the release of toxic compounds
like bilirubin and bilirubin conjugates from hepatocytes into sinu-
soidal space for their excretion via an alternative way through the
kidneys to limit cell injury (Donner and Keppler, 2001; Konig
et al., 1999; Ogawa et al., 2000; Teng and Piquette-Miller, 2007;
Vos et al., 1998). Another cytoprotective mechanism in case of
impaired biliary efﬂux is the downregulation of the uptake trans-
porters (Le Vee et al., 2009). These processes may explain the accu-
mulation of bilirubin and conjugated bilirubin in the blood in drug-
induced liver injury. Therefore, statin-mediated hepatotoxic effects
may result from the inhibition of hepatic uptake and/or the biliary
efﬂux of bilirubin and conjugated bilirubin.
Sandwich-cultured rat hepatocytes (SCRH) were used as an
in vitro model to assess the hepatotoxic potential of statins. Pres-
ently, only hepatocytes cultured in sandwich conﬁguration are suit-
able for the study of a two directional transport of endogenous
substances (including bilirubin and its conjugates) and drugs. SCRH
is closer to in vivo hepatocyte structure compared to hepatocytes in
conventional culture with re-established hepatic polarity, morpho-
logically and functionally formed bile canaliculi andmaintained key
hepatic functions (Berthiaume et al., 1996; Dunn et al., 1991;
LeCluyse et al., 2000).
In this study, we investigated the effects of multiple administra-
tions of atorvastatin, ﬂuvastatin, pravastatin, and rosuvastatin on
the functions of Mrp2 and Mrp3, involved in bilirubin disposition,
in addition to the assessment of Mrp2, Mrp3 and Oatp1a4 expres-
sion by Western blotting. Furthermore, we examined the modula-
tion of Mrp2 function by quantifying the biliary excretion of 5 (and
6)-carboxy-20,70-dichloroﬂuorescein (CDF), a commonly used Mrp2
probe substrate, in statin-treated hepatocytes.2. Methods
2.1. Materials
Atorvastatin and rosuvastatin were kindly provided by Gedeon
Richter Plc. (Budapest, Hungary). Fluvastatin and pravastatin were
a generous gift from Solvo Biotechnology (Szeged, Hungary).
Matrigel was from BD Biosciences (Bedford, MA). All chemicals,
including bilirubin, bovine serum albumin (BSA), dimethyl sulfox-
ide (DMSO), type IV collagenase, all cell culture media and reagents
were purchased from Sigma–Aldrich (Budapest, Hungary). All other
chemicals and reagents were of analytical grade and were readily
available from commercial sources unless stated otherwise in the
text. Stock solutions of test compounds were prepared in DMSO.Bilirubin (60 mM) was dissolved in DMSO/1.0 M NaOH (88:12) as
a stock solution and diluted to 3 mM in BSA (20 mg/ml). The ﬁnal
bilirubin concentration was 10 lM inWilliams’ Medium E. Six-well
plates were obtained from Greiner Bio-One (Mosonmagyarovar,
Hungary). Sterile collagen from rat tail was prepared in-house
according to established procedures.
2.2. Isolation and treatment of sandwich-cultured rat hepatocytes
Hepatocytes from adult male Wistar rats (Charles River,
Budapest) weighing 200–250 g were isolated by a previously
described three-step collagenase perfusion method (Lengyel
et al., 2005; Seglen, 1976). The protocol was approved by the Insti-
tutional Animal Care and Use Committee (Permit Number: 22.1/
2728/3/2011). All surgeries were performed under diethyl ether
anaesthesia, and all efforts were made to minimize suffering. Cell
viability (>90%) was routinely checked by the trypan blue exclu-
sion test. After preparation, freshly isolated cells were suspended
in Williams’ Medium E and plated at a cell density of 2  106
cells/well in six-well Greiner culture plates previously coated with
rat tail collagen. The cells were initially maintained in Williams’
Medium E supplemented with 5% of fetal calf serum (FCS),
0.1 lM insulin, 0.05 lM glucagon, 0.1 mg/ml gentamicin, 0.03 lM
Na2SeO3, and 0.1 lM dexamethasone and allowed to attach for
1 h at 37 C in a humidiﬁed incubator with 95% air/5% CO2. After
the cell attachment, the culture dishes were gently swirled, and
the medium was replaced. Calf serum was present for the ﬁrst
24 h, then omitted. In order to achieve sandwich conﬁguration, at
24 h after plating, the medium was aspirated and the cells were
overlaid with Matrigel basement membrane matrix at a concentra-
tion of 0.25 mg/ml in 1.5 ml of ice-cold serum-free Williams’ Med-
ium E. The culture medium was replaced every 24 h and the
studies were conducted on day 4 of culture.
Following the cell attachment, the hepatocytes were treated
with various concentrations (0.1, 1 and 10 lM) of atorvastatin,
ﬂuvastatin, pravastatin and rosuvastatin or the vehicle (0.1%
DMSO) as control daily for 3 days. Each statin concentration was
tested in three independent hepatocyte preparations using three
wells/treatment groups with each preparation.
2.3. Hepatobiliary disposition of bilirubin and conjugated bilirubin in
SCRH
Following the statin treatments of SCRH, on day 4, the
hepatobiliary transport of bilirubin and its conjugates was mea-
sured as described earlier (Lengyel et al., 2005). Brieﬂy, the culture
medium was removed and the cells were washed with HBSS buffer
containing calcium (standard buffer) at 37 C. The experiment was
started by the addition of 1 ml pre-warmed standard buffer contain-
ing 10 lM of bilirubin to all wells for 5 min at 37 C in a humidiﬁed
atmosphere of 95% air, 5% CO2. After the hepatocytes were loaded
with bilirubin, the loadingmediumwas removed, and the cellswere
washed vigorously three timeswith 1 ml of ice-cold standard buffer
or HBSS without Ca2+/Mg2+, containing1 mM EGTA (calcium-free
buffer) to stop bilirubin uptake. Thereafter, the hepatocytes were
incubated with standard or calcium-free efﬂuxmedium (HBSS, rep-
resenting the sinusoidal space) for 10 min. The efﬂux process was
terminated by the removal of the efﬂuxmedium, and thewells were
rinsedwith ice-cold standard buffer. Then, the cells were lysedwith
1 ml of an acetonitrile/water solution [30% (v/v)] by shaking for
20 min at 0 C and sonicated for an additional 5 min. The amounts
of bilirubin and bilirubin conjugates in the efﬂux medium and in
the cell lysates were analyzed by a high-performance liquid chro-
matography (HPLC) system. Data were normalized to the protein
content, which was determined by the method of Lowry et al.
(1951). Incubation in standard buffer maintains the integrity of
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bation in calcium-free buffer disrupts the tight junctions. The trans-
port of bilirubin and bilirubin conjugates into the bile canaliculi was
determined by subtracting the amount of bilirubin and its conju-
gates in standard buffer from that in calcium-free buffer and
expressed as nmol/mg protein. Each statin concentrationwas tested
in three independent hepatocyte preparations using three wells/
treatment groups with each preparation.
2.4. HPLC measurement of bilirubin and conjugated bilirubin
TheHPLCmethod for analyzing bilirubin and conjugated bilirubin
was performed as described previously (Lengyel et al., 2005) with
modiﬁcations. In brief, samples were centrifuged at 13,000 rpm for
10 min, and 200 ll of supernatant was analyzed on a Merck/Hitachi
HPLC system. Bilirubin and bilirubin conjugates were resolved on a
Chromolith Performance RP 18e (4.6  100 mm, Merck Darmstadt,
Germany) reversed-phase chromatographic column. Elution was
achieved at 3 ml/min ﬂow rate using a binary gradient of solvent A
(75% 0.01 M sodium phosphate buffer, pH 3.2 and 25% acetonitrile,
containing 200 ll/l triethylamine) and solvent B (acetonitrile) and a
total run time of 10 min. After 1 min of isocratic elution with solvent
A, the gradient started reaching 10% of eluent B in 5.2 min. Following
the separation of the conjugates, the column was rinsed of any
remaining hydrophobic components by using a gradient reaching
100% eluent B at 7.5 min, and then the column equilibration time
was 2.5 min. The UV absorbance was monitored at a wavelength of
450 nm. The amount of bilirubin and bilirubin conjugateswerequan-
tiﬁed using calibration curves prepared with bilirubin as standard.
The transport rate was estimated by the slope of the regression of
nanomoles of bilirubin or bilirubin conjugates excretedpermilligram
of hepatocyte protein.
2.5. Analysis of bile canaliculi formation and function
The bile canaliculi formation and functionwas veriﬁed byusing 5
(and 6)-carboxy-20,70-dichloroﬂuorescein diacetate (CDF-DA, Invit-
rogen), a speciﬁc Mrp2 substrate. The ﬂuorescent CDF, a metabolite
of CDF-DA is actively excreted into the bile canaliculi via Mrp2
(Zamek-Gliszczynski et al., 2003). Following the statin treatments
of SCRH for 3 days the cells were incubated with 2 lM CDF-DA in
standard buffer for 20 min at 37 C. The morphology of hepatocytes
and the accumulation of CDF in the bile canaliculi were observed
with an upright epiﬂuorescent microscope (Olympus BX61WI)
equipped with a FluoView300 confocal laser-scanning system
(Olympus, Tokyo, Japan) using 60 water immersion objective
(numeric aperture, 0.9). The ﬂuorescence measured with a green
ﬂuorescence of CDF excited at 488 nm was collected through a
510–530 nm bandpass ﬁlter. The interaction of statins with Mrp2-
mediated CDF transport was evaluated by quantifying the accumu-
lated ﬂuorescence in the bile canaliculi using ImageJ software
(http://rsb.info.nih.gov/ij/). The formation of bile canaliculi was
determined as area % of canaliculi compared to the total area.
2.6. Western blot studies of Oatp1a4, Mrp2 and Mrp3
The amount of Oatp1a4,Mrp2 andMrp3 proteinwas determined
semi-quantitatively by Western blotting of total cell lysates. After
3 days of statin treatment (10 lM), the cellswerewashed tree times
with ice-cold standard buffer and harvested in 200 ll of lysis buffer
consisting of 0.1 M Tris–HCl, pH 8.0, and protease inhibitor cocktail.
Anti-Oatp1a4 (M-50) and anti-Mrp3 (H-16) antibodies were sup-
plied by Santa Cruz Biotechnology (Santa Cruz, CA). Anti-Mrp2
(M2III-5) antibody was purchased from Alexis Biochemicals (Lau-
sanne, Switzerland). Goat anti-mouse and anti-rabbit horseradish
peroxidase-conjugated secondary antibodies were obtained fromSigma–Aldrich (Budapest, Hungary). The samples were normalized
for protein content, and 60 lg of each sample were separated using
7.5% SDS–polyacrylamide gel and transferred to polyvinylidenedi-
ﬂuoride membrane (Immobilon-P; Millipore, Bedford, MA) at
350 mA in a transfer buffer composed of 25 mM Tris, 192 mM
glycine, and 15% (v/v) methanol, pH 8.3. The membranes were trea-
tedwith blocking buffer (5% nonfat drymilk powder and 0.5% BSA in
phosphate-buffered saline with 0.05% Tween 20) for 2 h at room
temperature. The membranes were then incubated with the pri-
mary antibody, a rabbit anti-Oatp1a4 monoclonal antibody, a
mouse anti-Mrp2 monoclonal antibody or Mrp3 monoclonal
antibody, diluted 1:500, 1:2000 or 1:1000 in blocking buffer for
2 h at room temperature. After extensive washes with phosphate-
buffered saline/0.05% Tween 20 for 3  10 min at room
temperature, the membranes were incubated with the secondary
antibody, anti-rabbit or anti-mouse IgG-HRP, a horseradish peroxi-
dase-conjugated species-speciﬁc whole antibody diluted 1:5000 in
phosphate-buffered saline/0.05% Tween 20 for 1 h at room temper-
ature. Subsequently, the membranes were washed as described
above, and the immunoreactive bands were visualized with ECL
Western Blotting Detection System (GE Healthcare, Buckingham-
shire, UK). Densitometric scanning of protein bands was performed
using ImageJ software.2.7. Statistical analysis
Data were determined in triplicate from three individual livers
and are expressed as mean ± standard deviation (SD). Statistically
signiﬁcant differences in the uptake or the efﬂux of bilirubin and
its conjugates due to statin treatments were calculated using Stu-
dent’s t-test. In all cases, the criterion for statistical signiﬁcance
was p < 0.05.3. Results
3.1. Effects of statin treatment on the hepatobiliary transport of
bilirubin and conjugated bilirubin
Following the uptake of bilirubin by hepatocytes, its conjugated
metabolites are transported into the canalicular space and into the
medium by Mrp2 and Mrp3, respectively. The modulation of these
transport processes by multiple administrations of statins at differ-
ent concentrations was evaluated in SCRH. Lack of toxicity of the
statins in the experiments was proven by MTT test (data not pro-
vided). Fig. 1 summarizes the uptake and the total, two directional
efﬂuxes of bilirubin and conjugated bilirubin following a 3-day
treatment by 10 lM statin derivatives. The uptake of bilirubin is
presented as nmol/mg/5 min in Fig. 1A. Bilirubin uptake was
2.46 ± 0.20 nmol/mg/5 min in the control, which signiﬁcantly
decreased after treatment with atorvastatin, ﬂuvastatin, and rosu-
vastatin (1.84 ± 0.34, 1.99 ± 0.38, and 1.48 ± 0.31 nmol/mg/5 min,
respectively). Pravastatin did not alter the bilirubin uptake signiﬁ-
cantly (2.22 ± 0.39 nmol/mg/5 min). Statin treatments with lower
concentrations (0.1 and 1 lM) did not cause signiﬁcant difference
in bilirubin uptake compared to control. Similarly there was no sig-
niﬁcant effect at the lower concentrations concerning hepatobiliary
elimination of unconjugated and conjugated bilirubin obtained for
atorvastatin, ﬂuvastatin and pravastatin (data not shown). At
10 lM all statins but ﬂuvastatin signiﬁcantly increased the total
elimination of bilirubin metabolites compared to the control
(Fig. 1B). Though pravastatin did not alter the uptake, this drug
increased the elimination of conjugated bilirubin by nearly 50%.
Rosuvastatin treatment had the most pronounced effect on both
the hepatic uptake (60% of the control) and the elimination (190%
of the control) of bilirubin and its conjugates.
Fig. 1. The effects of statin treatment (10 lM) on the hepatic uptake of bilirubin (A)
and on the overall transport of conjugated bilirubin (B). Data were determined in
triplicate from three individual livers and are expressed as mean ± standard
deviation (SD). Statistically signiﬁcant differences in the uptake or the efﬂux of
bilirubin and its conjugates due to statin treatments were calculated using
Student’s t-test. In all cases, the criterion for statistical signiﬁcance was p < 0.05.
Fig. 2. The effects of statin concentration on the biliary efﬂux of conjugated bilirubin.
The results are presented as percentage of the control. Data were determined in
triplicate from three individual livers and are expressed as mean ± standard
deviation (SD). Statistically signiﬁcant differences in the uptake or the efﬂux of
bilirubin and its conjugates due to statin treatments were calculated using Student’s
t-test. In all cases, the criterion for statistical signiﬁcance was p < 0.05.
Fig. 3. The effects of statin treatment (10 lM) on the hepatic disposition of
conjugated bilirubin. Data were determined in triplicate from three individual livers
and are expressed as mean ± standard deviation (SD). Statistically signiﬁcant
differences in the uptake or the efﬂux of bilirubin and its conjugates due to statin
treatments were calculated using Student’s t-test. In all cases, the criterion for
statistical signiﬁcance was p < 0.05.
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conjugated bilirubin is presented in Fig. 2. At 0.1 lM none of the
statins inﬂuenced the Mrp2-mediated transport of conjugated bil-
irubin. Atorvastatin and ﬂuvastatin had little and not signiﬁcant
effect at the higher concentrations tested. In contrast, a signiﬁcant
and concentration-dependent increase of the biliary efﬂux was
observed in the pravastatin- and rosuvastatin-treated hepatocytes
compared to the non-treated cells. The canalicular efﬂux of the bil-
irubin metabolites was elevated to 135% and 190% by 1 and 10 lM
pravastatin and to 170% and 245 % by 1 and 10 lM rosuvastatin
(compared to untreated cells), respectively. All statins tested in this
study had no inﬂuence on the hepatic conjugation of bilirubin
(data not shown).
The canalicular, sinusoidal disposition and the intracellular
accumulation of conjugated bilirubin in control and statin treated
(10 lM) hepatocytes are shown in Fig. 3. Data are expressed as
the % of the uptake. The rate of net biliary and sinusoidal efﬂux
of conjugated bilirubin was 0.58 ± 0.27 nmol/mg/10 min and
0.31 ± 0.13 nmol/mg/10 min in control cells. Atorvastatin and
ﬂuvastatin did not alter the elimination proﬁle of bilirubinconjugates. Under the same conditions, treatment with pravastatin
elevated although not signiﬁcantly the biliary and decreased the
sinusoidal efﬂux, resulting in the shift of the direction of elimina-
tion towards the canalicular space. In the control SCRH the canalic-
ular transport was the double of the sinusoidal transport, and this
difference increased to four fold by 10 lM of pravastatin. Rosuvast-
atin treatment elevated the elimination of bilirubin metabolites
towards both directions (170% and 189% of the control, respec-
tively). As a result, the intracellular accumulation of the conjugated
bilirubin decreased by 46% changing the elimination proﬁle signif-
icantly (Fig. 3). As the proﬁle of conjugated bilirubin elimination
observed after rosuvastatin treatment highly differed from that
produced by any other statins examined, we focused on the con-
centration dependence of these effects. As shown in Fig. 4, rosu-
vastatin exhibited a concentration dependent inhibitory effect on
hepatic uptake and a stimulating effect on the biliary efﬂux, which
resulted in a signiﬁcantly reduced intracellular bilirubin level.
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Since the Mrp2-mediated transport of bilirubin conjugates was
modiﬁed by pravastatin and rosuvastatin treatment, we investi-
gated the inﬂuence of statins on Mrp2 function applying another,
Mrp2 speciﬁc substrate (CDF). Confocal laser scanning microscopy
was used to illustrate the transport of CDF into the bile canaliculi.
The ﬂuorescence images showed that CDF was mainly localized in
the canalicular networks after 20 min of incubation (Fig. 5A). The
ImageJ software was applied in order to quantify the change of bile
canaliculi formation (Fig. 5B). Atorvastatin-treated SCRH showed
similar canalicular network density as the control cells. Fluvastatin
slightly (151%) while pravastatin and rosuvastatin signiﬁcantly
(216% and275%of the control) increased the length of the canaliculi.
In addition, statin administration caused an apparent morphologi-
cal change in the bile canaliculi network, resulting in large dilated
canaliculi and an increase in canalicular branching.
3.3. Effects of statin treatment on the expression of Oatp1a4, Mrp2 and
Mrp3
To determine whether statin-induced reduction of bilirubin
uptake corresponded to altered protein expression of Oatp1a4,
we measured the expression level of this transporter via Western
blot hybridization. Fig. 6A shows a representative Western blot
of statin-treated rat hepatocytes demonstrating that ﬂuvastatin
and rosuvastatin had a signiﬁcant effect on Oatp1a4 expression
level. Fig. 6B shows that the expression level of Oatp1a4 in
ﬂuvastatin-treated group was decreased by 35% with respect to
the control, whereas in atorvastatin-treated group was only
slightly decreased (12%). Data showed that rosuvastatin treatment
resulted in a signiﬁcant decrease in the amount of Oatp1a4 protein
(70%) compared to the control.
The assumption that statin-induced elevation of the transport
activity of Mrp2 and Mrp3 is associated with elevated protein
levels was conﬁrmed by Western blot hybridization. Representa-
tive Western blots of Mrp2 and Mrp3 expression following sta-
tin-treatment are shown in Fig. 7A and B. Densitometric analyses
of the Western blots are shown in the lower panel (Fig. 7C). As
expected, the treatment of SCRH with 10 lM pravastatin and rosu-
vastatin produced marked increases in the amount of Mrp2 andFig. 4. Concentration dependent effects of rosuvastatin (up to 10 lM) on the
hepatic disposition of bilirubin. Data were determined in triplicate from three
individual livers and are expressed as mean ± standard deviation (SD). Statistically
signiﬁcant differences in the uptake or the efﬂux of bilirubin and its conjugates due
to statin treatments were calculated using Student’s t-test. In all cases, the criterion
for statistical signiﬁcance was p < 0.05.Mrp3 proteins (ranging from  50% to 80%), whereas no discernible
changes were observed by atorvastatin. There was a 37% increase
in Mrp2 and a 32% increase in Mrp3 protein expression in ﬂuvast-
atin-treated hepatocytes compared with the control by 72 h.4. Discussion
Rather small knowledge is available concerning the expression
and/or activity of MRP2 and MRP3 transporters in connection with
statin-induced liver injury; however, the functional alteration of
these transporters may explain the impaired hepatic trafﬁcking of
bilirubin, which is considered as a sensitive signal of hepatotoxicity.
The down-regulation of Mrp2/MRP2 transporter has been charac-
terized in both rodents and primary human hepatocytes (Kullak-
Ublick et al., 2002; Trauner et al., 1997). Particularly, statins may
limit the hepatic elimination of bilirubin by blocking different path-
ways associated with bilirubin disposition including both the
uptake and the efﬂux processes. Our objective was to characterize
the alteration of the hepatobiliary transport of bilirubin and its con-
jugates following multiple treatments with four statin derivatives,
atorvastatin, ﬂuvastatin, pravastatin, and rosuvastatin. In the pres-
ent study, SCRH was applied as an in vitromodel, in order to enable
to examine the two directional transport processes involved, such
as the uptake and the efﬂux on the sinusoidal and the efﬂux on
the canalicular membrane surface. The methodology used allowed
us to measure the uptake, the sinusoidal and the canalicular efﬂux
and the intracellular accumulation of bilirubin and its conjugates,
simultaneously. Preliminary viability studies conﬁrmed that the
statins applied in the drug interaction experiments were not cyto-
toxic for SCRH even at the highest concentration used. Statins were
administered daily for 3 days in order to monitor their longer term
effect on bilirubin elimination. Atorvastatin, ﬂuvastatin, and rosu-
vastatin effectively inhibited the hepatic uptake of bilirubin, which
is mostly taken up by Oatp1a4 (Fig. 1A) (Reichel et al., 1999; Roy
Chowdhury et al., 2001). This observation directly correlates with
our Western blot data on Oatp1a4 expression in statin-treated rat
hepatocytes (Fig. 6). Furthermore, our results imply that these stat-
ins shared the same transporters as bilirubin and this might also
cause the decrease of bilirubin uptake. This is in accord with previ-
ous reports indicating that Oatps play a crucial role in the uptake of
statins in rats (Nezasa et al., 2003; Sakamoto et al., 2008; Sugatani
et al., 2010; Watanabe et al., 2009). On the contrary, pravastatin
did not alter the uptake rate of bilirubin. This can be attributed to
the fact that pravastatin is a substrate for more Oatps, namely,
Oatp1a1 and Oatp1b2 but not for Oatp1a4 (Bergwerk et al., 1996;
Hsiang et al., 1999; Sasaki et al., 2004), which is involved in the
uptake of bilirubin (Reichel et al., 1999; Roy Chowdhury et al.,
2001). Moreover, administration of pravastatin (5 mg/kg) signiﬁ-
cantly increased the expression level of Oatp1a4 in vivo in rat liver
(Kolouchova et al., 2011). However, both pravastatin and rosuvast-
atin are low permeable, hydrophilic drugs and are known to be
excreted extensively into the bile as unchanged compounds in rats
(Kitamura et al., 2005; Yamazaki et al., 1997); our results concern-
ing the inhibitory effectiveness of the two drugs towards bilirubin
uptake, also support that their uptake mechanisms might be differ-
ent. This is in good agreement with previously published data,
which showed that the uptake clearance of rosuvastatin was
approximately 10-fold higher than that of pravastatin in rats
(Nezasa et al., 2003). In addition, the uptake clearance of atorva-
statin and ﬂuvastatin determined in rat hepatocyteswere alsomore
than 10-fold higher compared to pravastatin (Watanabe et al.,
2010).
Atorvastatin, pravastatin and rosuvastatin enhanced the two
directional elimination of conjugated bilirubin (Fig. 1B). It is well
published that xenobiotics often induce metabolic enzymes and
Fig. 5. The effects of statin treatment on the bile canaliculi network formation in SCRH. Hepatocytes were treated daily for 3 days with atorvastatin, ﬂuvastatin, pravastatin
and rosuvastatin (10 lM), or the vehicle (0.1% DMSO) as control. SCRH were incubated with 5 (and 6)-carboxy-20 ,70-dichloroﬂuorescein diacetate (CDFDA) (2 lM) for 20 min
at 37 C under 5% CO2 in air. In the cells, endogenous esterases cleave the cell-permeable dye. The resulting CDF is excreted into the bile canaliculi (bright green segments) via
Mrp2. Fluorescence images (A) and corresponding ﬂuorescent results (B). Data were determined in triplicate from three individual livers and are expressed as
mean ± standard deviation (SD). Statistically signiﬁcant differences in the uptake or the efﬂux of bilirubin and its conjugates due to statin treatments were calculated using
Student’s t-test. In all cases, the criterion for statistical signiﬁcance was p < 0.05. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the
web version of this article.)
Fig. 6. The effects of statin treatment on the expression of Oatp1a4. Typical patterns
of Western blot analysis of Oatp1a4 in statin-treated rat hepatocytes. Hepatocytes
were treated daily for 3 dayswith atorvastatin, ﬂuvastatin and rosuvastatin (10 lM),
or the vehicle (0.1% DMSO) as control. Total proteins were extracted from the cells
andwestern blot for Oatp1a4 (A) was performed.Mean densitometrymeasurements
(± SD) from three individual livers (B). Results of the densitometric analysis are given
as percentage of the controls. P < 0.05 statistically signiﬁcantly different from the
control. Ctrl, control; A, atorvastatin; F, ﬂuvastatin; R, rosuvastatin; Oatp, organic
anion-transporting polypeptide.
Fig. 7. The effects of statin treatment on the expression of Mrp2 and Mrp3. Typical
patterns of Western blot analysis of Mrp2 and Mrp3 in statin-treated rat
hepatocytes. Hepatocytes were treated daily for 3 days with atorvastatin,
ﬂuvastatin, pravastatin and rosuvastatin (10 lM), or the vehicle (0.1% DMSO) as
control. Total proteins were extracted from the cells and western blots for Mrp2 (A)
and Mrp3 (B) protein were performed. Mean densitometry measurements (±S.D)
from three individual livers (C). Results of the densitometric analysis are given as
percentage of the controls. P < 0.05 statistically signiﬁcantly different from the
control. Ctrl, control; A, atorvastatin; F, ﬂuvastatin; P, pravastatin, R, rosuvastatin;
Mrp, multidrug resistance-associated protein.
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to copewith the continuously changing chemical environment. Pre-
vious studies have demonstrated that all statins tested in this study
are both substrates and inhibitors for Mrp2 in experiments using
membrane and vesicle preparations, hepatocytes, and in vivo (Abe
et al., 2008; Ellis et al., 2013; Yamazaki et al., 1997). At the same
time, ﬂuvastatin treatment did not affect the rate of bilirubin efﬂux,
the interpretation of which might be that different transport pro-
cesses are involved in the elimination of ﬂuvastatin and bilirubin.
This result is consistent with a previous study (Watanabe et al.,
2010) revealing a minor contribution of any canalicular transporter
to the elimination of ﬂuvastatin in rats, since just 9% of the oral dose
was recovered in the bile in male SD rats. In our study, the elevated
expression of the Mrp2 protein in response to rosuvastatin and
pravastatin treatments supports that the accelerated bilirubin
efﬂux was due to the induction of this transporter (Fig. 7). In accord
with our results, pravastatin treatment in vivo (5 mg/kg) signiﬁ-
cantly increased the expression level of Mrp2 in rats (Kolouchova
et al., 2011).
Another important ﬁnding of the current study is the unique
effect of statins on bile canalicular network formation (Fig. 5). The
mechanisms by which statins regulate canalicular network forma-
tion are unknown yet; however, we think that it is connected with
the increased Mrp2 expression. An analogue mechanism has been
described by Fu et al. (2011), who showed that taurocholate, a sub-
strate for another canalicular transporter (Bsep, bile salt export
pump), stimulates hepatocyte polarization and accelerates the can-
alicular network formation in SCRH. Under the inﬂuence of statins,
the number and size of bile canaliculi signiﬁcantly increased and
they formed a more complex, branching architecture. These bile
canaliculi were functional as demonstrated by the Mrp2-mediated
CDF transport. Summing up, statin treatment rather seems to
induce choleresis than cholestasis, as it was demonstrated in
Fig. 5. We believe that our observation is the ﬁrst experimental evi-
dence concerning the effect of statins on cell polarization and bile
canaliculi formation.
Rosuvastatin was the only statin which remarkably stimulated
both the sinusoidal and biliary efﬂux of conjugated bilirubin
(Fig. 3). The results observed at the transport activity level could
be detected also at the protein level (Fig. 7). The exact mechanisms
involved in the increased expression of Mrp2 and Mrp3 are not
known, and further investigations of this phenomenon are obvi-
ously required. Kobayashi et al. (2013) demonstrated that pitavast-
atin treatment induced the expression of MRP2/Mrp2 through an
SREBP regulatory pathway in HepG2 cells and rat liver.
By inhibiting bilirubin uptake and stimulating unconjugated and
conjugated bilirubin elimination, rosuvastatin may have a potential
role in liver protection through maintaining intracellular bilirubin
level low, as we have demonstrated (Fig. 3). The observed effect
was concentration-dependent (Fig. 4). The inhibition of bilirubin
uptake and the stimulation of the sinusoidal elimination of conju-
gated bilirubin by statins may explain, at least in part, the clinical
observation of elevated serum bilirubin levels. It is generally
assumed that the high hepatocellular concentration of bilirubin is
the primary determinant of drug-induced hepatotoxicity. Based
on our ﬁndings, elevated serum bilirubin levels may not necessarily
be an appropriate indicator of hepatotoxicity associated with statin
treatment. In other words, an increased serum bilirubin level not
inevitably refers to the hepatotoxic potential of statins, since an ele-
vated serum concentration does not correlate with higher intracel-
lular bilirubin concentrations. In addition, Muchova et al. (2007)
reported that the long-term use of statins induced heme oxygen-
ase-1 (HMOX1) inmice and through the intervention of upregulated
HMOX1 (conversion of heme into bilirubin) activity increased
serum and tissue bilirubin concentrations in vivo. Additionally,
serum bilirubin concentrations are inﬂuenced by many factorsincluding, dietary, intake of numerous drugs, gender, race, and age
(Vítek and Schwertner, 2007).
In summary, we have demonstrated for the ﬁrst time that stat-
ins modulate bilirubin uptake and elimination. Our results indicate
that rosuvastatin remarkably reduced the intracellular concentra-
tion of bilirubin and conjugated bilirubin by decreasing bilirubin
uptake via Oatp1a4, increasing biliary excretion via Mrp2 and sinu-
soidal elimination via Mrp3. We showed that statins exerted their
effect by simultaneously suppressing Oatp1a4 protein and induc-
ing Mrp2, Mrp3 proteins. Rosuvastatin and pravastatin accelerated
cell polarization and canalicular network formation in SCRH. Taken
together, these results suggest that the alteration of Mrp2 and
Mrp3 transport activity by statins is not associated with enhanced
intracellular bilirubin concentration in rat hepatocytes. Conse-
quently, the cholestatic cases reported probably were not due to
intracellular hepatotoxicity caused by statin treatment.
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